TTAX-03 is under clinical development by BioTissue and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TTAX-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TTAX-03 overview

TTAX-03 is under development for the treatment of facet joint osteoarthritis pain. The therapeutic candidate comprises morselized cryopreserved amniotic membrane (CAM) and cryopreserved umbilical cord (CUC). It is administered through intraarticular route. being developed based on CryoTek technology. The therapeutic candidate is a lyophilized and micronized particulate human amniotic and umbilical cord.

BioTissue overview

BioTissue, formerly Tissuetech, is a biotechnology company that develops human amniotic and umbilical cord tissue products for wounds, ocular and musculoskeletal conditions. Its Prokera corneal bandages are used to treat damaged corneas; AmnioGraft improves surgical outcomes of various eye and skin diseases; and AmnioGuard helps in ocular surface reconstruction and management. The company also offers Neox 100, an amniotic membrane allograft to heal shallow and larger wounds; Neox 1K and Neox RT allografts to cure acute and chronic wounds; Clarix 100, a thinner graft and Clarix 1K, a thicker graft for various surgical applications. It utilizes Cryotek, a proprietary tissue-processing method that conserves the inherent integrity of natural placental tissue; and SteriTek preservation process to protect tissues. BioTissue is headquartered in Miami, Florida, the US.

For a complete picture of TTAX-03’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.